The Series D funding will support a prospective pancreatic cancer study and the expansion of the company’s San Diego laboratory operations.
Craif Inc, a bio-AI company developing a urine analysis platform for the early detection of cancer, raised approximately $34 million in Series D financing. The funding round was co-led by Granite-Integral, a joint venture between Granite Asia and Integral Corp, and Tauns Co Ltd, a manufacturer of rapid diagnostic tests.
The company will use the proceeds to strengthen research and development at its San Diego laboratory, prepare for a reimbursement-driven launch of its noninvasive cancer test in the US, and advance a regulatory filing in Japan for a software-based medical device targeting pancreatic cancer diagnosis. This latest round brings the company’s total capital raised to roughly $90 million since its founding in 2018.
Craif’s platform uses artificial intelligence to analyze microRNA in urine. Its flagship test, miSignal, is currently offered at more than 2,500 medical institutions and 4,500 pharmacies in Japan, where more than 100,000 tests have been performed to date.
“Craif has proven in Japan that a non-invasive urine test can detect cancer early and at scale, and we believe the same approach can unlock massive unmet demand in the United States,” says CK Choun, co-head, Granite-Integral, in a release.
US Clinical Expansion and Leadership
A central component of the company’s US strategy is scaling operations at its San Diego facility, which opened in April 2026. This includes a prospective clinical study of the urine-based test for pancreatic cancer, an indication where the company states the clinical utility and path to reimbursement are clear. The test is intended to help clinicians determine which patients require further workup, such as magnetic resonance imaging or endoscopic ultrasound, and which can safely wait.
To lead these clinical efforts, Craif appointed Nick Bevins, MD, PhD, as chief medical officer. Bevins is a board-certified clinical pathologist and has served as a Clinical Laboratory Improvement Amendments laboratory director at several biotechnology and diagnostics companies.
“I joined Craif because the company has built a differentiated platform, generated an extraordinary body of clinical evidence in Japan, and is committed to advancing science through rigorous data rather than hype,” says Nick Bevins, chief medical officer of Craif, in a release. “Urine will play an increasingly important role in the future of early disease detection because it offers a non-invasive window into human biology.”
The expansion follows the relocation of CEO Ryuichi Onose to San Diego to lead the US business. Takeo Mukai also joined the company this year as chief financial officer, having previously held leadership roles at Medtronic.
“What we are building goes beyond a single cancer test,” says Onose in a release. “The earliest signals of many diseases show up in urine, and reading them is what Craif is really about. Cancer is the first step.”
The Series D round also included participation from US-based Unreasonable, X&KSK, and various institutional and individual investors across Singapore, the US, and Japan. The financing comprised approximately $30.7 million in equity and $3.3 million in debt.
ID 206531968 © Tatiana Sviridova | Dreamstime.com
